Tesamorelin and Ipamorelin are both studied in growth-hormone-axis research, but they act on two different arms of GH release: the GHRH receptor and the growth-hormone-secretagogue receptor.
At a glance
| Property | Tesamorelin | Ipamorelin |
|---|---|---|
| Class | Stabilized GHRH analog | Selective GH secretagogue (peptide) |
| Primary research target | GHRH receptor | GHS-R1a (ghrelin receptor) |
| Research domain | Somatotropic / lipid-metabolism | Selective GH-secretion signaling |
| Selectivity note | GHRH-pathway | Low cross-activity in models |
| Format | Lyophilized powder | Lyophilized powder |
Tesamorelin in research
Tesamorelin is a stabilized GHRH analog studied for GHRH-receptor signaling in somatotropic-axis and lipid-metabolism research models. See the full Tesamorelin research profile.
Ipamorelin in research
Ipamorelin is a selective growth-hormone secretagogue studied as a GHS-R1a (ghrelin-receptor) agonist, noted in research models for selective GH-secretion signaling. See the full Ipamorelin research profile.
Key differences
- Tesamorelin targets the GHRH receptor; Ipamorelin targets the GHS-R1a ghrelin receptor.
- They represent two complementary arms of GH-release research.
- Both are supplied as lyophilized research peptides.
Selecting for a research model
Researchers select between Tesamorelin and Ipamorelin based on which GH-release pathway, GHRH or GHS-R, is under study. These distinctions are described strictly in the context of research models and are not statements of efficacy, safety, or suitability for any use.
Both Tesamorelin and Ipamorelin ship from Vantage Aminos with a batch-specific Certificate of Analysis (HPLC purity and mass-spectrometry identity), U.S. synthesized for research use.
For research use only. Not for human or veterinary use.
- HPLC + MS tested, every batch
- U.S. synthesized
- Batch COA on the product page
